APA (7th ed.) Citation

Salvia, G., Bevilacqua, M., Manzo Margiotta, F., Michelucci, A., Granieri, G., Fidanzi, C., . . . Mazzatenta, C. (2024). Switch from adalimumab to brodalumab as a possible trigger factor for the onset of pyoderma gangrenosum. Australasian Journal of Dermatology, 65(4), e111. https://doi.org/10.1111/ajd.14266

Chicago Style (17th ed.) Citation

Salvia, Giorgia, Matteo Bevilacqua, Flavia Manzo Margiotta, Alessandra Michelucci, Giammarco Granieri, Cristian Fidanzi, Valentina Dini, Marco Romanelli, and Carlo Mazzatenta. "Switch from Adalimumab to Brodalumab as a Possible Trigger Factor for the Onset of Pyoderma Gangrenosum." Australasian Journal of Dermatology 65, no. 4 (2024): e111. https://doi.org/10.1111/ajd.14266.

MLA (9th ed.) Citation

Salvia, Giorgia, et al. "Switch from Adalimumab to Brodalumab as a Possible Trigger Factor for the Onset of Pyoderma Gangrenosum." Australasian Journal of Dermatology, vol. 65, no. 4, 2024, p. e111, https://doi.org/10.1111/ajd.14266.